CRITICAL ANALYSIS OF AYURVEDIC PHARMACOTHERAPY IN PEDIATRIC OBESITY: MOLECULAR MECHANISMS, CLINICAL EVIDENCE, AND SAFETY DYNAMICS- NARRATIVE REVIEW
DOI:
https://doi.org/10.22159/prl.ijayush.vi.2566Keywords:
Pediatric obesity; Sthaulya; Triphala; Guggulu; molecular mechanisms; pharmacovigilance.Abstract
Pediatric obesity is a chronic, relapsing and multifactorial disease in which pharmacotherapy must improve cardiometabolic risk without compromising nutrition, linear growth, puberty or psychological health. This narrative review critically examines Ayurvedic pharmacotherapy for pediatric obesity through traditional rationale, molecular plausibility, clinical evidence and safety surveillance. In 2022, more than 390 million people aged 5-19 years were overweight and over 160 million were living with obesity. Classical Ayurveda describes Sthaulya/Atisthaulya as excessive Meda accumulation associated with over-nourishing food, inadequate activity, disordered appetite and constitutional susceptibility, and proposes Langhana, Rukshana, Lekhana, Dipana-Pachana, dietary regulation and exercise. Triphala, Guggulu-containing formulations, Navaka Guggulu and Vachaharidradi Gana Vati are frequently discussed, but pediatric efficacy data are extremely limited. A Triphala systematic review included 12 randomized studies and 749 participants, predominantly adults; five studies reported reductions in weight-related outcomes, but heterogeneity and risk of bias restrict certainty. One randomized trial in 130 adolescents reported a between-group BMI difference of approximately -1.4 kg/m2 after three months with a proprietary plant formulation, whereas a 2025 pediatric comparison of Navaka Guggulu and Vachaharidradi Gana Vati remained a trial protocol rather than definitive outcome evidence. Mechanistic work suggests anti-adipogenic and multi-target metabolic signalling, but laboratory and computational findings cannot establish pediatric clinical benefit. Safety concerns include gastrointestinal reactions, variable composition, developmental pharmacology, herb-drug interactions, contamination and under-reporting of adverse events. Ayurvedic medicines should therefore remain adjunctive to family-based lifestyle treatment, be restricted to quality-assured products under qualified supervision, and be evaluated in adequately powered pediatric trials with growth, pubertal, metabolic and pharmacovigilance outcomes.
Downloads
References
World Health Organization. Obesity and overweight [Internet]. Geneva: World Health Organization; 2025 Dec 8 [cited 2026 Sep 4].
Khadilkar V, Shah N, Harish R, Ayyavoo A, Bang A, Basu S, et al. Indian Academy of Pediatrics revised guidelines on evaluation, prevention and management of childhood obesity. Indian Pediatr. 2023;60(12):1013-1031. doi:10.1007/s13312-023-3066-z.
Agnivesha. Charaka Samhita, revised by Charaka and Dridhabala, with Ayurveda-Dipika commentary of Chakrapanidatta. Acharya YT, editor. Varanasi: Chaukhambha Surbharati Prakashan; 2011. Sutrasthana 21.
Green BN, Johnson CD, Adams A. Writing narrative literature reviews for peer-reviewed journals: secrets of the trade. J Chiropr Med. 2006;5(3):101-117. doi:10.1016/S0899-3467(07)60142-6.
Goyal R, Goyal M, Chandola HM. A clinical study on the role of Agnimanthadi compound and Vashpa Svedana in the management of Sthaulya (obesity). Ayu. 2013;34(4):390-396. doi:10.4103/0974-8520.127721.
Phimarn W, Sungthong B, Itabe H. Effects of Triphala on lipid and glucose profiles and anthropometric parameters: a systematic review. J Evid Based Integr Med. 2021;26:2515690X211011038. doi:10.1177/2515690X211011038.
Inpan R, Sakuludomkan C, Na Takuathung M, Koonrungsesomboon N. Network pharmacology revealing the therapeutic potential of bioactive components of Triphala and their molecular mechanisms against obesity. Int J Mol Sci. 2024;25(19):10755. doi:10.3390/ijms251910755.
Shivakumar S, Ilango K, Dubey GP, Subhasree N, Agrawal A. Evaluation of plant based formulation on adolescent obesity and its associated bio-markers: a randomized, double blind, placebo controlled study. Complement Ther Med. 2015;23(2):157-164. doi:10.1016/j.ctim.2015.01.012.
World Health Organization. WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems. Geneva: World Health Organization; 2004.
Hampl SE, Hassink SG, Skinner AC, Armstrong SC, Barlow SE, Bolling CF, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640. doi:10.1542/peds.2022-060640.
Fadnavis KK, Rathi RB, Ratnaparkhi KS, Rathi BJ, Deshmukh PR. Evaluation of the comparative efficacy of Navak Guggulu versus Vachaharidradi Gana Vati in the management of Sthaulya (overweight) in children: protocol for a randomized controlled trial. JMIR Res Protoc. 2025;14:e58838. doi:10.2196/58838.
Banjare J, Raina P, Mansara P, Ghanekar RK, Bhalerao S. Triphala regulates adipogenesis through modulation of expression of adipogenic genes in 3T3-L1 cell line. Pharmacogn Mag. 2018;13(Suppl 4):S834-S839. doi:10.4103/pm.pm_153_17.
Jose J, Rao PGM, Kamath MS, Jimmy B. Drug safety reports on complementary and alternative medicines (Ayurvedic and homeopathic medicines) by a spontaneous reporting program in a tertiary care hospital. J Altern Complement Med. 2009;15(7):793-797.
doi:10.1089/acm.2008.0128.
